Over the past two decades, treatment options for patients with multiple sclerosis (MS) have
increased exponentially. In the current therapeutic landscape, “no evidence of MS disease …

Background Data are scarce on immunogenicity of COVID-19 vaccines in patients with
autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to …

Methods| This is a prospective cohort study conducted at the MS Center Amsterdam in
Amsterdam, the Netherlands. On July 31, 2020, all adult patients with a current diagnosis of MS …

Background Disease-specific studies have reported impaired humoral responses after
SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated with …

The socioeconomic burden of COVID-19 and pressure on health-care systems can only be
reduced by achieving herd immunity against SARS-CoV-2. For herd immunity to be achieved…

Objective To determine whether natalizumab efficacy is maintained when switching to
personalized extended interval dosing based on individual natalizumab trough concentrations in …

Here, we provide an extensive overview of all reported COVID-19 cases in multiple sclerosis
(MS) patients in the Netherlands between 27 February and 9 June 2020, gathered by the …

Background Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …

Background: Patients affected by different types of autoimmune diseases, including common
conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated …

Background and Objectives To investigate the potential of serum neurofilament light (NfL) to
reflect or predict progression mostly independent of acute inflammatory disease activity in …